In Brief
This article was originally published in The Tan Sheet
Executive Summary
Novartis appeals Excedrin case to NARB
You may also be interested in...
National Advertising Division In Brief
Combe ends “alarmist” tone in claims; comparative claims require more than placebo trials; use of FDA logo in ad triggers review; and Excedrin to discontinue speed claims.
National Advertising Division In Brief
Combe ends “alarmist” tone in claims; comparative claims require more than placebo trials; use of FDA logo in ad triggers review; and Excedrin to discontinue speed claims.
New Products In Brief
Chloraseptic pops out line extensions